210 related articles for article (PubMed ID: 33726759)
21. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
22. Quantified postsurgical small cell size CTCs and EpCAM
Wang L; Li Y; Xu J; Zhang A; Wang X; Tang R; Zhang X; Yin H; Liu M; Wang DD; Lin PP; Shen L; Dong J
Cancer Lett; 2018 Jan; 412():99-107. PubMed ID: 29031565
[TBL] [Abstract][Full Text] [Related]
23. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
[TBL] [Abstract][Full Text] [Related]
24. Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma.
Zhou J; Zhang Z; Zhou H; Leng C; Hou B; Zhou C; Hu X; Wang J; Chen X
BMC Cancer; 2020 Oct; 20(1):1047. PubMed ID: 33129301
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between glypican-3 and Notch1 expressions in hepatocellular carcinoma].
Peng F; Wu Z; Li X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):590-2, 597. PubMed ID: 23644127
[TBL] [Abstract][Full Text] [Related]
26. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma.
Prasoppokakorn T; Buntho A; Ingrungruanglert P; Tiyarattanachai T; Jaihan T; Kulkraisri K; Ariyaskul D; Phathong C; Israsena N; Rerknimitr R; Treeprasertsuk S; Chaiteerakij R
Sci Rep; 2022 Nov; 12(1):18686. PubMed ID: 36333384
[TBL] [Abstract][Full Text] [Related]
28. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
29. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
30. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
31. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts Metastasis and Prognoses.
Yin LC; Luo ZC; Gao YX; Li Y; Peng Q; Gao Y
Biomed Res Int; 2018; 2018():3789613. PubMed ID: 30046595
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma.
Shioga T; Kondo R; Ogasawara S; Akiba J; Mizuochi S; Kusano H; Mihara Y; Tanigawa M; Kinjyo Y; Naito Y; Kuromatsu R; Nakashima O; Yano H
Anticancer Res; 2020 Jul; 40(7):4105-4113. PubMed ID: 32620659
[TBL] [Abstract][Full Text] [Related]
33. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma.
Ou H; Huang Y; Xiang L; Chen Z; Fang Y; Lin Y; Cui Z; Yu S; Li X; Yang D
Dig Dis Sci; 2018 Sep; 63(9):2373-2380. PubMed ID: 29926241
[TBL] [Abstract][Full Text] [Related]
37. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
[TBL] [Abstract][Full Text] [Related]
38. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363
[TBL] [Abstract][Full Text] [Related]
39. The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.
Zhao L; Zheng Z; Liu Y; Liu F; Li X; Wu Z
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6035-6048. PubMed ID: 36633681
[TBL] [Abstract][Full Text] [Related]
40. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
